August 13, 2024 at 4:20 pm

Stocks Rally Ahead of CPI Report as Bond Yields Decline: Markets Wrap

Inflation and Market Movement:Stocks rallied and bond yields fell as the latest U.S. inflation data reinforced expectations that the Federal Reserve might cut interest rates in September. The S&P 500 rose by 1.5%, led by gains in major technology companies, while the Nasdaq 100 climbed 2.2%, and the Russell 2000 increased by 1.3%. Treasuries gained… [Read More]
August 13, 2024 at 4:04 pm

SKYX Raises Ceiling on Q2 Sales Reporting Record Revenues of $21.4M as it Penetrates US and Canadian Markets

The smart platform technology and lighting company, SKYX Platforms Corp (SKYX) announced its second quarter earnings that generated a record $21.4M in revenues compared to the same period last year of $15M. Additionally, its second quarter cash position was reported at $15.6M. This quarter the company collaborated with Home Depot, a global retail leader in… [Read More]
August 13, 2024 at 11:19 am

The Sky is the Limit: CXApp (CXAI) Releases Q2 Earnings, Inks Multi-Year Agreement with Google Cloud, Surges Over 80%

PRISM NextGen Tech and AI Index company, CXApp (CXAI) has announced Q2 2024 financial results that included a major business transformation to an AI-native SaaS model. The company saw 78% renewal and expansion bookings from previous year, reported its largest expansion deal with major enterprise customer in the financial sector that grew this customers reoccurring… [Read More]
August 12, 2024 at 1:17 pm

FDA Rejects MDMA Therapy for PTSD: A Blow Against Psychedelic Research

The Food and Drug Administration (FDA) has dealt a blow to the emerging field of psychedelic therapy by rejecting an application from Lykos Therapeutics for approval to administer MDMA as part of therapy for people suffering with post-traumatic stress disorder (PTSD). The ruling is a major setback for the psychedelic medicine revolution, which has been… [Read More]
August 12, 2024 at 1:08 pm

Biotech Mover Lipella (LIPO) Doses First Two Patients in Phase 2a Trial

Today the clinical stage biotechnology company Lipella Pharmaceuticals (LIPO) announced the dosing of the first two patients with LP-310 in its Phase 2a clinical trial in Oral Lichen Planus (OLP) patients. Approximately 6M Americans suffer from OLP, a chronic inflammatory condition affecting mucous membranes in the mouth that can cause burning and pain in addition… [Read More]
August 09, 2024 at 4:40 pm

No Tesla? No Problem. ChargePoint (CHPT) Launches Charging Connector That Fits Almost Every EV

PRISM Emerging EV Index company ChargePoint (CHPT) provides network charging solutions for EVs and has unveiled ChargePoint® Omni Port, an innovative EV connector solution that ensures any EV can charge in any parking space, regardless of connector type, without requiring an expensive additional cable. Omni Port eliminates the need for drivers to carry adapters, removes… [Read More]
August 09, 2024 at 4:13 pm

FSD Pharma Stock Surges 200% as unbuzzd™ Set to Shake Up the Recovery Market

PRISM Emerging Psychedelic Index top gainer, FSD Pharma Inc. (NASDAQ: HUGE) saw its shares skyrocket by 200% today after providing an update on its investment in Celly Nutrition Corp., a Canadian company set to launch an innovative product, unbuzzd™, later this month. Celly Nutrition, supported by FSD Pharma’s pharmaceutical research and development team, is introducing… [Read More]
August 09, 2024 at 3:38 pm

S&P 500 Set for Best Two-Day Run of 2024 Amid Market Rebound

A late-week rally is positioning the S&P 500 for its best two-day advance of 2024, offering a stark contrast to the market turmoil seen earlier in the week. Following a rollercoaster of ups and downs—including a panic-driven selloff on Monday—the S&P 500 is now close to avoiding what would have been its longest stretch of… [Read More]